Discovery of the once-weekly glucagon-like peptide-1 (Glp-1) analogue semaglutide
Adult patients with type 2 diabetes inadequately controlled on metformin (1500 mg/day) and Januvia (100 mg/day) for at least 90 days prior to screening (N=407) were randomized 1:1 to switch to once-daily Victoza 1.8 mg in addition to a Januvia placebo or continued Januvia 100 mg in addition to a Victoza placebo, both in combination with metformin
Table of Contents Understanding the GLP-1 market landscape Navigating safety and regulatory scrutiny Differentiation in a saturated market Building trust through patient-centered messaging Understanding the Evolving GLP-1 Market Landscape The GLP-1 category has grown rapidly, driven by demand for weight management and diabetes care
Patients should report any side effects to their healthcare provider, who can advise on management strategies and adjust treatment if necessary
Mounjaro (tirzepatide) is generally covered by Anthem for type 2 diabetes management, even when plans exclude GLP-1 coverage for weight loss alone
Yes, Saxenda belongs to a class of medications called glucagon-like-peptide-1 (GLP-1) receptor agonists